Intrinsiqq
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. Financials

ABOS

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 6 available years
Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
2:1 split
DEC 2021
48:1 split
General & Administrative$19$20$19$13$7
Research & Development$105$94$42$32$12
Total Operating Expenses$124$114$61$45$20
Operating Income-$124-$114-$61-$45-$20
Non-Operating
Net Interest Expense$3$10$10$0–
Other Non-Operating Income (Expense)$2$12$9$2-$81
Income Tax Expense$0$0$0$0$0
Net Income
Net Income-$121-$102-$52-$43-$101
EPS (Basic)-$2.00-$1.71-$1.08-$1.06-$5.02
EPS (Diluted)-$2.00-$1.71-$1.08-$1.06-$5.02
Weighted Avg Shares (Basic)60.6M60.0M48.6M40.6M20.1M
Weighted Avg Shares (Diluted)60.6M60.0M48.6M40.6M20.1M
Shares Outstanding60.6M60.0M48.6M40.6M20.1M

Acumen Pharmaceuticals (ABOS) financials: revenue, profit and margins

Acumen Pharmaceuticals (ABOS) generated about n/a in revenue and -$104 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Acumen Pharmaceuticals profitable?+

Acumen Pharmaceuticals reported about -$104 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 21 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 27 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ABOS

CompareIntrinsic value
PALIPalisade Bio Inc.
$0.84-9.69%20
VYGRVoyager Therapeutics Inc.
$1.53-4.97%10
FENCFennec Pharmaceuticals Inc.
$13.10-2.60%50
RGNXRegenxbio Inc.
$7.16-0.28%36
NVAXNovavax Inc.
$7.47-3.24%25
TECHBio-Techne Corporation
$72.67-0.04%41
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
LCTXLineage Cell Therapeutics Inc.
$0.77-5.87%10

Held by ETFs

ABOS is in 2 US ETFs. The largest of them, with ABOS's weight in each:

Spot a number that looks wrong? Check it in ABOS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ABOS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.